ChEMBL ligand: CHEMBL468 (NSC-527179, Thalidomide, Thaled, NSC-66847, Distaval, .alpha.-phthalimidoglutarimide, Contergan, Pantosediv, Pharmion, Thalidomide bms (previously thalidomide celgene), Myrin, Neurosedyn, Kevadon, Talidex, Softenon, N-phthalylglutamic acid imide, Thalidomide lipomed, Talidomida, Thalomid, K-17, Celgene)
Cereblon isoform 4 in Magnetospirillum gryphiswaldense [ChEMBL: CHEMBL3763007] [UniProtKB: A4TVL0] There should be some charts here, you may need to enable JavaScript!
Glyceraldehyde-3-phosphate dehydrogenase, cytosolic in Leishmania mexicana [ChEMBL: CHEMBL4137] [UniProtKB: Q01558] There should be some charts here, you may need to enable JavaScript!
Interleukin-1 beta in Human [ChEMBL: CHEMBL1909490] [UniProtKB: P01584] There should be some charts here, you may need to enable JavaScript!
Prostaglandin G/H synthase 1 in Sheep [ChEMBL: CHEMBL2949] [UniProtKB: P05979] There should be some charts here, you may need to enable JavaScript!
Prostaglandin G/H synthase 2 in Sheep [ChEMBL: CHEMBL4102] [UniProtKB: P79208] There should be some charts here, you may need to enable JavaScript!
cereblon/Protein cereblon in Human [ChEMBL: CHEMBL3763008] [GtoPdb: 3086] [UniProtKB: Q96SW2] There should be some charts here, you may need to enable JavaScript!
Tumor necrosis factor in Human [ChEMBL: CHEMBL1825] [UniProtKB: P01375] There should be some charts here, you may need to enable JavaScript!
Zinc finger protein Aiolos in Human [ChEMBL: CHEMBL4739707] [UniProtKB: Q9UKT9] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
Cereblon isoform 4 in Magnetospirillum gryphiswaldense (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3763007] [UniProtKB: A4TVL0]
ChEMBL	Inhibition of MANT-uracil binding to Magnetospirillum gryphiswaldense cereblon isoform 4 Y101F mutant by Cheng-Prusoff equation analysis	B	5.02	pKi	9600	nM	Ki	J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL	Inhibition of MANT-uracil binding to wild type Magnetospirillum gryphiswaldense cereblon isoform 4 by Cheng-Prusoff equation analysis	B	5.36	pKi	4400	nM	Ki	J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL	Inhibition of MANT-uracil binding to wild-type Magnetospirillum gryphiswaldense CRBN isoform 4 by FRET assay	B	5.36	pKi	4400	nM	Ki	J Med Chem (2019) 62: 6615-6629 [PMID:31251063]
ChEMBL	Inhibition of MANT-uracil binding to Magnetospirillum gryphiswaldense cereblon isoform 4 Y101F mutant by FRET assay	B	4.97	pIC50	10700	nM	IC50	J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL	Inhibition of MANT-uracil binding to wild type Magnetospirillum gryphiswaldense cereblon isoform 4 by FRET assay	B	5.11	pIC50	7800	nM	IC50	J Med Chem (2016) 59: 770-774 [PMID:26730808]
Glyceraldehyde-3-phosphate dehydrogenase, cytosolic in Leishmania mexicana (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4137] [UniProtKB: Q01558]
ChEMBL	cytomteric bead array (CBA) assay: The Fix buffer I was warmed up to 37° C. in an incubator or water bath prior to use. The Perm Buffer III was chilled in a â¿¿20° C. freezer prior to use. The cells were collected at the end of treatment with testing compounds. One volume of the pre-warmed Fix Buffer I was mixed with one volume of cell suspension. If the volume of the cell suspension is greater than 100 uL, the cells were spun and resuspended in 100 uL medium or PBS. The buffer and the cell suspension were mixed well and incubated in a 37° C. water bath for 10 min. The cells were spun down at 250ÿg for 10 min and the supernatant was aspirated. The cells were washed once with BD Stain Buffer. The pellet was spun and the supernatant was removed. The cells were vortexed to be loosened, and permeabilized by slowly adding cold Perm Buffer III while vortexing or mixing. Subsequently, the cells were incubated on ice for 30 min. The cells were then spun down and washed twice with Stain Buffer. The supernatant was spun and aspirated. The cells were resuspended in a small volume of Stain buffer (50 or 100 uL containing from 200,000 to 1 million cells). Anti-IKFZ3 antibody was added to the cell suspension at 1:1000 dilution and incubated for 45 min at 4° C. The cells were then spun down and washed once with stain buffer. Secondary antibody was added to the cells at 1:5000 dilution and incubated at room temperature for 20 min in the dark. The cells were washed once with stain buffer prior to analysis by FACS.	B	5	pIC50	>10000	nM	IC50	US-9694015-B2. Methods for the treatment of locally advanced breast cancer (2017)
Interleukin-1 beta in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1909490] [UniProtKB: P01584]
ChEMBL	cytomteric bead array (CBA) assay: The Fix buffer I was warmed up to 37° C. in an incubator or water bath prior to use. The Perm Buffer III was chilled in a â¿¿20° C. freezer prior to use. The cells were collected at the end of treatment with testing compounds. One volume of the pre-warmed Fix Buffer I was mixed with one volume of cell suspension. If the volume of the cell suspension is greater than 100 uL, the cells were spun and resuspended in 100 uL medium or PBS. The buffer and the cell suspension were mixed well and incubated in a 37° C. water bath for 10 min. The cells were spun down at 250ÿg for 10 min and the supernatant was aspirated. The cells were washed once with BD Stain Buffer. The pellet was spun and the supernatant was removed. The cells were vortexed to be loosened, and permeabilized by slowly adding cold Perm Buffer III while vortexing or mixing. Subsequently, the cells were incubated on ice for 30 min. The cells were then spun down and washed twice with Stain Buffer. The supernatant was spun and aspirated. The cells were resuspended in a small volume of Stain buffer (50 or 100 uL containing from 200,000 to 1 million cells). Anti-IKFZ3 antibody was added to the cell suspension at 1:1000 dilution and incubated for 45 min at 4° C. The cells were then spun down and washed once with stain buffer. Secondary antibody was added to the cells at 1:5000 dilution and incubated at room temperature for 20 min in the dark. The cells were washed once with stain buffer prior to analysis by FACS.	B	5	pIC50	>10000	nM	IC50	US-9694015-B2. Methods for the treatment of locally advanced breast cancer (2017)
Prostaglandin G/H synthase 1 in Sheep (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2949] [UniProtKB: P05979]
ChEMBL	Inhibitory activity (RA1) against Prostaglandin G/H synthase 1 was calculated relative to aspirin	B	6.43	pIC50	370	nM	IC50	Bioorg Med Chem Lett (2002) 12: 1043-1046 [PMID:11909713]
Prostaglandin G/H synthase 2 in Sheep (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4102] [UniProtKB: P79208]
ChEMBL	Inhibitory activity (RA2) against Prostaglandin G/H synthase 2 was calculated relative to aspirin	B	6.3	pIC50	500	nM	IC50	Bioorg Med Chem Lett (2002) 12: 1043-1046 [PMID:11909713]
cereblon/Protein cereblon in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3763008] [GtoPdb: 3086] [UniProtKB: Q96SW2]
ChEMBL	Binding affinity to CRBN (unknown origin) assessed as dissociation constant by TR-FRET assay	B	6.6	pKd	250	nM	Kd	Eur J Med Chem (2024) 263: 115950-115950 [PMID:37984298]
ChEMBL	Binding affinity to CRBN (unknown origin) assessed as dissociation constant	B	6.6	pKd	250	nM	Kd	Eur J Med Chem (2023) 257: 115492-115492 [PMID:37210838]
GtoPdb	Determined in a BiaCore assay using immobilised thalidomide and recombinant cereblon protein.	-	8.07	pKd	8.5	nM	Kd	Science (2010) 327: 1345-50 [PMID:20223979]
ChEMBL	Inhibition of MANT-uracil binding to human CRBN (delta 1 to 315) by Cheng-Prusoff equation analysis	B	4.64	pKi	22700	nM	Ki	J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL	Binding affinity to human CRBN TBD (319 to 425 residues) assessed as inhibition constant by MST assay	B	5.07	pKi	8550	nM	Ki	Bioorg Med Chem Lett (2024) 110: 129858-129858 [PMID:38917956]
ChEMBL	Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence in presence of 0.5% DMSO by MST based assay	B	5.07	pKi	8510	nM	Ki	ACS Med Chem Lett (2021) 12: 74-81 [PMID:33488967]
ChEMBL	Binding affinity to human CRBN thalidomide binding domain assessed as inhibition constant by microscale thermophoresis analysis	B	5.07	pKi	8500	nM	Ki	Eur J Med Chem (2023) 246: 114990-114990 [PMID:36476642]
ChEMBL	Binding affinity to human CRBN TBD assessed as inhibition constant using BODIPY-uracil as substrate by Microscale thermophoresis assay	B	5.07	pKi	8500	nM	Ki	Eur J Med Chem (2024) 270: 116328-116328 [PMID:38552426]
ChEMBL	Binding affinity to CRBN (unknown origin) assessed as inhibition constant by FRET assay	B	5.36	pKi	4400	nM	Ki	J Med Chem (2023) 66: 3173-3194 [PMID:36821822]
ChEMBL	Binding affinity to GST-tagged wild-type human CRBN incubated for 3 hrs by TR-FRET assay	B	5.74	pKi	1800	nM	Ki	J Med Chem (2024) 67: 14125-14154 [PMID:39132814]
ChEMBL	Binding affinity to CRBN (unknown origin) assessed as inhibition constant	B	5.74	pKi	1800	nM	Ki	J Med Chem (2023) 66: 13280-13303 [PMID:37683104]
ChEMBL	Inhibition of MANT-uracil binding to human CRBN (delta 1 to 315) by FRET assay	B	4.52	pIC50	29900	nM	IC50	J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL	Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence in presence of 0.5% DMSO by MST based assay	B	4.64	pIC50	22900	nM	IC50	ACS Med Chem Lett (2021) 12: 74-81 [PMID:33488967]
ChEMBL	Binding affinity to GST-tagged wild type human CRBN incubated for 3 hrs by TR-FRET assay	B	5.54	pIC50	2900	nM	IC50	J Med Chem (2023) 66: 12559-12585 [PMID:37647546]
ChEMBL	Inhibition of biotinylated thalidomide binding to CRBN (40 to 442 residues) (unknown origin) incubated for 1 hrs by HTRF assay	B	5.57	pIC50	2700	nM	IC50	J Med Chem (2024) 67: 9194-9213 [PMID:38829718]
ChEMBL	Displacement of fluorescent tracer from NanoLuc-tagged CRBN (unknown origin) by NanoBRET assay	B	5.83	pIC50	1490	nM	IC50	RSC Med Chem (2023) 14: 501-506 [PMID:36970148]
Tumor necrosis factor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1825] [UniProtKB: P01375]
ChEMBL	cytomteric bead array (CBA) assay: The Fix buffer I was warmed up to 37° C. in an incubator or water bath prior to use. The Perm Buffer III was chilled in a â¿¿20° C. freezer prior to use. The cells were collected at the end of treatment with testing compounds. One volume of the pre-warmed Fix Buffer I was mixed with one volume of cell suspension. If the volume of the cell suspension is greater than 100 uL, the cells were spun and resuspended in 100 uL medium or PBS. The buffer and the cell suspension were mixed well and incubated in a 37° C. water bath for 10 min. The cells were spun down at 250ÿg for 10 min and the supernatant was aspirated. The cells were washed once with BD Stain Buffer. The pellet was spun and the supernatant was removed. The cells were vortexed to be loosened, and permeabilized by slowly adding cold Perm Buffer III while vortexing or mixing. Subsequently, the cells were incubated on ice for 30 min. The cells were then spun down and washed twice with Stain Buffer. The supernatant was spun and aspirated. The cells were resuspended in a small volume of Stain buffer (50 or 100 uL containing from 200,000 to 1 million cells). Anti-IKFZ3 antibody was added to the cell suspension at 1:1000 dilution and incubated for 45 min at 4° C. The cells were then spun down and washed once with stain buffer. Secondary antibody was added to the cells at 1:5000 dilution and incubated at room temperature for 20 min in the dark. The cells were washed once with stain buffer prior to analysis by FACS.	B	5	pIC50	>10000	nM	IC50	US-9694015-B2. Methods for the treatment of locally advanced breast cancer (2017)
Zinc finger protein Aiolos in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4739707] [UniProtKB: Q9UKT9]
ChEMBL	Induction of ePL tagged Aiolos degradation in human DF15 cells incubated for 4 hrs by luminescence based assay	B	6.48	pEC50	330	nM	EC50	J Med Chem (2023) 66: 16388-16409 [PMID:37991844]

ChEMBL data shown on this page come from version 36:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]